Evidence map›Paper›PMID 40136861›Full record

ArticleGels (Basel, Switzerland)2025

Development of Dual-Crosslinking N-Isopropylacrylamide-Based Injectable Hydrogel for Transcatheter Embolization in Swine Model.

Amrita Pal, Gabriel Zdrale, Michelle Loui, Jeff Blanzy, William Bichard, Thomas J On, Yuan Xu, Oscar Alcantar-Garibay, Mark C Preul, Brent L Vernon

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amrita PalSchool of Biological and Health Systems Engineering, Center for Interventional Biomaterials, Arizona State University, Tempe, AZ 85287-9709, USA.
Gabriel ZdraleSchool of Biological and Health Systems Engineering, Center for Interventional Biomaterials, Arizona State University, Tempe, AZ 85287-9709, USA.ORCID 0000-0002-4183-4031
Michelle LouiSchool of Biological and Health Systems Engineering, Center for Interventional Biomaterials, Arizona State University, Tempe, AZ 85287-9709, USA.ORCID 0009-0005-9097-3213
Jeff BlanzySchool of Biological and Health Systems Engineering, Center for Interventional Biomaterials, Arizona State University, Tempe, AZ 85287-9709, USA.
William BichardThe Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Thomas J OnThe Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA.ORCID 0009-0005-7449-4204
Yuan XuThe Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA.ORCID 0000-0003-1959-9861
Oscar Alcantar-GaribayThe Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Mark C PreulThe Loyal and Edith Davis Neurosurgical Research Laboratory, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Brent L VernonSchool of Biological and Health Systems Engineering, Center for Interventional Biomaterials, Arizona State University, Tempe, AZ 85287-9709, USA.ORCID 0000-0002-3288-0327

Funding

Dignity Health dba. St. Joseph's Hospital and Medical Center MMSA AWD00033004
6 · The paper itself

Abstract

For decades, endovascular embolization (EE) has been a common technique for the treatment of several vascular abnormalities where the affected vessel is occluded using biocompatible embolic agents. In this work, we developed a NIPAAm-based temperature responsive, dual-crosslinking biocompatible and non-toxic injectable hydrogel system as a liquid embolic agent for EE. The swelling and mechanical properties of the hydrogel were tuned and optimized for its in vivo application. The in vivo study was carried out with nine swine models, including three animals for exploratory study and six animals for acute confirmatory study for the occlusion of surgically created aneurysm and rete mirabile. The polymer hydrogel was delivered into the vascular malformation sites using a catheter guided by angiography. After the injection, the liquid embolic agent was transformed into a solid implant in situ via cross-linking through chemical and thermal processes. During the exploratory study, it was observed that one of the three aneurysms and all the RMs were occluded. During the acute confirmatory study, all the aneurysms and the RMs of six animals were successfully occluded. Overall, our study presents the construction and characterization of a novel injectable hydrogel system capable of successfully occluding vascular malformation in large animals. In the future, after further modification and validation, this material may be used as a liquid embolic agent in clinical studies.

Indexed as

aneurysmembolic agentendovascular embolizationinjectable hydrogelocclusionpoly(NIPAAm)rheology

Identifiers

PMID40136861
PMCPMC11942042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.